Drugs / MPLA
MPLA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01584115 | Jul 2012 → Jul 2013 | lung cancer, melanoma, ovarian cancer | Instituto de Investigação em Imunologia | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT07077616 Background | Jul 2025 → Dec 2027 expected | glioma | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05772286 Background | Jul 2023 → Jun 2025 overdue | — | Fundacion Clinic per a la Recerca Biomédica | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05208125 Background | Mar 2022 | HIV infectious disease | IrsiCaixa | Completed | No outcome recorded |
| Phase 1 | NCT03961438 Comparator | Nov 2019 → Jun 2022 | HIV infectious disease | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1 | NCT03408262 Background | Oct 2017 → Feb 2020 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPLA | “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗4“Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg)” NCT05208125 ↗ |
| Known as | CN54gp140/MPLA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03408262 ↗ |
| Known as | monophosphoryl lipid A | “TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)” NCT07077616 ↗1“monophosphoryl lipid A (MPLA) liposomes” NCT03961438 ↗ |
| Modality | Other / unclassified | “adjuvanted with monophosphoryl lipid A (MPLA) liposomes” NCT03961438 ↗ |
| Route | Intramuscular | “I.M. CN54gp140/MPLA” NCT03408262 ↗ |